These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 5354523)

  • 1. [Effect of aluminum hydroxide on serum calcium, serum phosphorus and calcium turnover in uremic patients].
    Friis T; Weeke E
    Nord Med; 1969 Sep; 82(37):1136-42. PubMed ID: 5354523
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of aluminum hydroxide in serum calcium, serum phosphorus and calcium turnover in uraemic patients.
    Friis T; Weeks E
    Calcif Tissue Res; 1968; ():Suppl:58. PubMed ID: 5721079
    [No Abstract]   [Full Text] [Related]  

  • 3. [Changes in the serum calcium and the serum phosphorus in persons with uremia and in normal persons after administration of sodium phytate- and aluminum hydroxide].
    Friis T; Hahnemann S; Weeke E
    Ugeskr Laeger; 1967 Oct; 129(42):1380-4. PubMed ID: 4870663
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of aluminium hydroxide (Aludrox) upon serum calcium, serum calcium, serum phosphorus, and calcium 47 turnover in uraemic patients.
    Friis T; Weeks E
    Acta Med Scand; 1970; 187(1-2):41-8. PubMed ID: 5423205
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of aluminium on the development of hyperparathyroidism and bone disease in the azotaemic rat.
    Felsenfeld AJ; Machado L; Bover J; Trinidad P; Rodriguez M
    Nephrol Dial Transplant; 1993; 8(4):325-34. PubMed ID: 8390007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total urinary hydroxyproline in osteomalacia and the effect upon it of treatment with vitamin D.
    Smith R; Dick M
    Clin Sci; 1968 Feb; 34(1):43-56. PubMed ID: 5640685
    [No Abstract]   [Full Text] [Related]  

  • 7. Distortions of bone cell metabolism in uremia and their cause.
    Nichols G; Flanagan B; Veer Jv
    Arch Intern Med; 1969 Nov; 124(5):530-8. PubMed ID: 5345859
    [No Abstract]   [Full Text] [Related]  

  • 8. [Studies on the therapy of uremic osteopathy].
    Schaefer K; Schaefer P; Koeppe P; Opitz A; Höffler D
    Dtsch Med Wochenschr; 1969 Jan; 94(2):70-2. PubMed ID: 5782692
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal tubular acidosis and amino-aciduria in osteomalacia of dietary or intestinal origin.
    Muldowney FP; Freaney R; McGeeney D
    Q J Med; 1968 Oct; 37(148):517-39. PubMed ID: 5696365
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum-aluminum in nondialyzed chronic uremic patients before and during treatment with aluminum-containing phosphate-binding gels.
    Brahm M
    Clin Nephrol; 1986 May; 25(5):231-5. PubMed ID: 3720033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The treatment of nephritic or uremic acidosis].
    Euchenhofer M; Würz H; Streicher E
    Wien Med Wochenschr; 1971 Jun; 121(24):495-8. PubMed ID: 5094455
    [No Abstract]   [Full Text] [Related]  

  • 14. [Calcitonin sensitivity testing in patients with kidney diseases. Changes in serum calcium, phosphorus and plasma cyclic adenosine monophosphate levels under the effect of calcitonin in healthy subjects and uremic patients under chronic hemodialysis].
    Szücs J; Steczek K
    Orv Hetil; 1978 May; 119(20):1220-4. PubMed ID: 206866
    [No Abstract]   [Full Text] [Related]  

  • 15. [On the clinical aspects and therapy of renal osteopathy].
    Sommerkamp H; Rodeck G; Hupe K
    Bruns Beitr Klin Chir (1971); 1965 Sep; 211(2):222-30. PubMed ID: 5865523
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
    Brickman AS; Coburn JW; Sherrard DJ; Wong EG; Norman AW; Singer FR
    Contrib Nephrol; 1980; 18():29-41. PubMed ID: 7353378
    [No Abstract]   [Full Text] [Related]  

  • 17. [Osteomalacia from phosphate-binding substances (author's transl)].
    Emanuelli C; Borghi M; Pecchini F
    Ateneo Parmense Acta Biomed; 1975; 46(6):577-87. PubMed ID: 1222067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum calcium and serum phsophorus in uraemia during administration of osdium phytate and aluminium hydroxide.
    Friis T; Hahnemann S; Weeke E
    Acta Med Scand; 1968 Jun; 183(6):497-505. PubMed ID: 5703643
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone mineral density profile in uremic and renal transplant patients.
    Chao SH; Tsai KS; Chieng PU; Lee PH; Lee CJ; Lee CS
    Transplant Proc; 1994 Aug; 26(4):2009-11. PubMed ID: 8066651
    [No Abstract]   [Full Text] [Related]  

  • 20. Proximal renal tubular acidosis associated with osteomalacia.
    Ahmed A; Sims RV
    South Med J; 2001 May; 94(5):536-9. PubMed ID: 11372811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.